Design and optimization of enzyme nanocarriers for targeted drug delivery in cancer therapy

Project Abstract

The development of targeted drug delivery systems has revolutionized cancer therapy by enhancing therapeutic efficacy while minimizing systemic toxicity. This research focuses on the design and optimization of enzyme nanocarriers tailored for precise delivery of anticancer agents, harnessing the unique catalytic properties of enzymes to improve drug activation within tumor microenvironments. The primary objective was to engineer nanocarriers capable of encapsulating diverse therapeutic compounds, maintaining enzyme activity, and selectively targeting cancer cells through functionalized surface modifications. Initial synthesis involved the fabrication of biocompatible nanoparticles, such as liposomes and polymeric nanocarriers, followed by the conjugation or encapsulation of specific enzymes like catalase, glucose oxidase, and matrix metalloproteinases, known for their roles in tumor physiology. Optimization protocols included varying parameters like particle size, surface charge, enzyme loading efficiency, and stability under physiological conditions, employing techniques such as dynamic light scattering (DLS), zeta potential analysis, and transmission electron microscopy (TEM). Targeting specificity was enhanced via surface functionalization with ligands such as folic acid, antibodies, or peptides that recognize overexpressed receptors on cancer cells, verified through in vitro binding assays and confocal microscopy. The enzyme activity post-encapsulation was assessed through spectrophotometric assays, demonstrating retained catalytic functions vital for prodrug activation or reactive oxygen species (ROS) generation within tumor sites. In vitro cytotoxicity tests using cancer cell lines evaluated the therapeutic potential of the nanocarriers, revealing increased cell death rates owing to targeted delivery and localized enzyme activity. Additionally, stability assessments under simulated physiological conditions highlighted the robustness of the nanocarriers, affirming their suitability for in vivo applications. The research also involved computational modeling to predict nanocarrier behavior and optimize parameters for maximal tumor accumulation and minimal off-target effects. Results indicated that enzyme-loaded nanocarriers significantly improved drug uptake by cancer cells, reduced systemic side effects, and achieved controlled release profiles. Key challenges such as enzyme denaturation and nonspecific uptake were addressed through surface modifications and encapsulation techniques. The study's findings underscore the potential of enzyme nanocarriers as versatile platforms for targeted cancer therapy, opening avenues for personalized medicine approaches. Future work will focus on in vivo efficacy and toxicity studies, alongside exploring multimodal therapeutic strategies integrating imaging agents for theranostic applications. This research advances the understanding of enzyme nanocarrier design, providing a foundation for future clinical translation aimed at improving therapeutic outcomes for cancer patients.

Project Overview

This project is about creating tiny carriers, called nanocarriers, that can deliver medicines directly to cancer cells. Scientists are interested in using enzymes, which are natural proteins that help speed up chemical reactions, as part of these carriers. The idea is to design a system that can recognize cancer cells, attach to them, and release the medicine exactly where it is needed, instead of affecting the whole body. This targeted approach helps reduce the side effects usually associated with chemotherapy and increases the chances of successfully killing the cancer cells. The project addresses the problem that current cancer treatments often harm healthy cells along with cancer cells, leading to unpleasant side effects and sometimes limiting the amount of medicine that can be safely given. By designing enzyme-based nanocarriers, the project aims to improve the precision of drug delivery and make cancer treatments more effective and safer. The researcher will start by reviewing existing scientific studies on nanocarriers, enzymes, and targeted drug delivery. Then, they will design and create different types of nanocarriers using materials that are safe and compatible with the body. Next, they will incorporate enzymes into these carriers to improve their ability to recognize and attach to cancer cells. The researcher will then test these nanocarriers in laboratory settings to see how well they can deliver drugs to cancer cells in a controlled environment. Adjustments will be made to optimize the size, stability, and targeting ability of the nanocarriers based on initial test results. Finally, the researcher will analyze all the data to determine which design works best for targeting cancer cells efficiently. The expected outcome is a set of optimized enzyme nanocarriers that can successfully deliver drugs directly to cancer cells, minimizing damage to healthy tissues. This project could pave the way for developing more effective and safer cancer treatments in the future.